Athersys (ATHX) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $0.06 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.14. Analysts had a consensus of $-0.08. The company posted revenue of $15.45 million in the period, compared to analysts expectations of $.55 million. The company’s revenue was up 2016.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.16 EPS.
Many Wall Street Analysts have commented on Athersys. Company shares were Reiterated by Maxim Group on Mar 11, 2016 to “Buy”, Firm has raised the Price Target to $ 10 from a previous price target of $5 .
Athersys closed down -0.01 points or -0.43% at $2.32 with 3,93,305 shares getting traded on Wednesday. Post opening the session at $2.28, the shares hit an intraday low of $2.25 and an intraday high of $2.35 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Mar 21, 2016, William Jr Lehmann (President and COO) sold 25,000 shares at $2.41 per share price. According to the SEC, on Sep 21, 2015, John J Harrington (Exec Vice Pres and CSO) sold 8,150 shares at $1.36 per share price. On Sep 21, 2015, Bokkelen Gil Van (Chairman and CEO) sold 9,500 shares at $1.36 per share price, according to the Form-4 filing with the securities and exchange commission.
Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders neurological conditions cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications such as obesity related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas including the treatment of ARDS. Its current programs include Ischemic Stroke Acute Myocardial Infarction Acute Respiratory Distress Syndrome Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs it is also conducting or supporting clinical activity in other areas such as solid organ transplant.